Topic: endogenous neurogenesis

Our previous study found that ectomesenchymal stem cells derived from human pluripotent stem cells (hPSC-EMSCs) exhibited higher neuroprotective potential than hUC-MSCs, as evidenced by a more significant reduction in lesion size and apoptosis in rat brains after hypoxia-ischemia (HI). Moreover, in vitro studies demonstrated that hPSC-EMSC-derived conditioned medium (CM) had neuroprotective and neurorestorative effects through the promotion of anti-apoptosis, neurite growth and neurogenesis. In this study, we discovered that hPSC-EMSCs and hUC-MSCs expressed differential secreted factors by ut

Hypoxic-ischaemic encephalopathy (HIE) is one of the most serious complications in neonates and infants. Mesenchymal stromal cell (MSC)-based therapy is emerging as a promising treatment avenue for HIE. However, despite its enormous potential, the clinical application of MSCs is limited by cell heterogeneity, low isolation efficiency and unpredictable effectiveness. In this study, we investigated the therapeutic effects of human pluripotent stem cell-derived ectomesenchymal stromal cells (hPSC-EMSCs) and human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) in a rat model of HIE. Lesi